Navigation Links
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Date:1/15/2009

CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Peptimmune, Inc. ("Peptimmune"), a privately held biotechnology company, announced today that it has granted Novartis (NYSE: NVS) an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune's multiple sclerosis drug candidate. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Peptimmune.

In the event that Novartis exercises the option to PI-2301, Novartis would assume the global clinical development, manufacturing, and marketing of PI-2301 and all associated costs. Peptimmune would receive payments upon the option exercise and upon successful completion of certain development, regulatory, and commercial milestones. These payments together could total more than $500 million. In addition, Peptimmune shall be eligible to receive royalties on product sales. Additional terms were not disclosed.

"We believe that Novartis represents an outstanding future partner for Peptimmune and the global development of PI-2301. This option agreement provides Peptimmune with access to both Novartis' world class development expertise and the necessary capital to invest in this proprietary product," said Thomas P. Mathers, President and CEO of Peptimmune.

Todd Foley, Managing Director at MPM Capital commented, "Peptimmune and its world-leading expertise in peptide copolymers represent an attractive investment opportunity."

About PI-2301

PI-2301 is a peptide copolymer developed using Peptimmune's novel platform peptide chemistry. PI-2301 is designed to enhance the regulatory response of the immune system, thereby controlling the pathogenic autoimmune response in certain diseases. PI-2301 is currently in Phase 1b development by Peptimmune.

<
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Peptimmune Announces the Second Close of Series D Private Financing
2. Tufts receives NIH grant to study obesity prevention in new immigrants
3. Floridas Uninsured and Underinsured to Benefit from Statewide Grants
4. Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008
5. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
6. The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative
7. Life Sciences Discovery awards health research program grants
8. Blue Cross Foundation Awards $660,000 in Grants to Improve Community Health
9. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
10. UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity
11. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)....Y.,Nov.27/PRNewswire-USNewswire/--Preventingdisea...everyyear,newvaccinesarebeingaddedtoassistindiseas...eperiodoftime?And,ifnot,whenareadditional,boosters...,sissueofPediatrics,theJournaloftheAmericanAcademy...esterGeneralResearchInstitute,basedatRochesterGene...
(Date:11/27/2009)... XenaCare Holdings has announced that it has...tion, one of the largest nonprofit organizations d...ducation. , Delray Beach,..., Inc. (OTCBB: XCHO), a company specializing in th...althcare products, has announced today that is has...
(Date:11/27/2009)....27/PRNewswire/-- Allrecipes.com , theworld,s#1fo...rs,withmorethan2.8millionvisitorsthedaybeforeThank...biggestfoodholidayoftheyear.TheaverageThanksgiving...centincreasefromlastyear,sfeast.AccordingtotheAllr...opularThanksgivingrecipe,acontrastfromlastyear,spo...
(Date:11/27/2009)... Specialist manufacturers who use medical lo... millions of dollars by bringing in technology par...ng numbers of pro-active medical manufacturers are...pt stage of their projects, ensuring that progress...ses or potentially outdated technology. , ...
(Date:11/26/2009)....J.,Nov.27/PRNewswire/--Thediabetespopulationinthe...nnualmedicalspendingonthediseaseisprojectedtohit$3...publishedintheDecemberissueof DiabetesCare .TheNat...mofNovoNordisk,commissionedtheanalysisbyateamfromt...t,thenumberofAmericanslivingwithdiabeteswillrisefr...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3
...e Senior Living Inc. (NYSE: BKD ) announced toda...to a Second Amended and Restated Credit Agreement....million revolving loan facility and matures in Aug... the aggregate. The letter of credit facilities m...
...in Shapiro, PhD, have collaborated for 20 years to...center at Barrow Neurological Institute at St. Jos...dedicated patient care and research, the Shapiros ... allow Barrow to hire the best and the brightest t...
... MD Salon & Hair Replacement Center, Hair Fant...cement services for clients battling with hair los... Greenbelt, MD (PRWEB) February 27, 2009 -- ...amage, side effects from medication, iron or zinc ...
...utes to a Healthier, More Productive Practice , ,...ented integration of technology and is well-positi... The new A-dec 300 system offers customers a mid-l...cts. , , (Photo: http://www.newscom.com/cgi-bi...
...n of Wound Care and Ophthalmics Business of Unomed...ble Healthcare Partners ("RoundTable"), an operati...y on the healthcare industry, announced today that...cal Limited ("Unomedical") based in Redditch, U.K....
... global clinical research organization announced t...post of Director, Late Phase, Europe. , , Ms. T...w position in Chiltern,s global Late Phase Organiz...operational side of management in both industries....
Other Medicine News:Health News:Brookdale Amends and Extends Corporate Line of Credit 2Health News:Brookdale Amends and Extends Corporate Line of Credit 3Health News:A lifetime of paying it forward 2Health News:Inspired Cancer Survivor Launches Customized Hair Replacement ,Techniques at Award-Winning Hair Salon 2Health News:New A-dec 300(TM) Offers Dentists an Innovative Equipment Solution 2Health News:RoundTable Healthcare Partners Leads Portfolio Company Add-On Acquisition 2Health News:RoundTable Healthcare Partners Leads Portfolio Company Add-On Acquisition 3Health News:Chiltern Appoints Jane Turner as Late Phase Director for Europe 2
(Date:11/25/2009)...v.25/PRNewswire/--BioTrendsResearchGroup,Inc.relea...t,thefirstinamulti-phasesyndicatedmarketresearchpr...lara,fromproductlaunchthroughthefirstsixmonthsofav...informationfrom75uniqueDermatologistsandqualitativ...nduseofStelara,obstaclestouse,typicalpatienttypes,...
(Date:11/25/2009)...Md.,Nov.25/PRNewswire-USNewswire/--RemediumTechnol...thatstopsseverebleeding,wonfirstprizeand$10,000int...rityChallenge2009,companyofficialsannouncetoday. ,...rld,Remedium,steampitchedtheirinventionattheGSCSec...ss. ,, Remedium( www.remediumtechnologies.com )...
(Date:11/25/2009)...,Nov.25/PRNewswire-Asia-FirstCall/--ChinaSkyOne,Me...daq: CSKI ),a,leadingfullyintegratedpharmaceutical...sinthePeople,sRepublicofChina("PRC"),today,announc...stitutefor,theControlofPharmaceuticalandBiological...s:itsDiagnosticKitforHumanProstateSpecific,Antigen...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 1REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 2REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 3U S Census Bureau Daily Feature for Sept 20 57708 1Strain on nanocrystals could yield colossal results 14156 1Strain on nanocrystals could yield colossal results 14156 2Strain on nanocrystals could yield colossal results 14156 3
...lls Inc. (BCI), a,biopharmaceutical company utiliz...p compounds that promote the growth of new neurons... diseases, announced today that it has,initiated a...didate,BCI-540, for the treatment of depression wi... expressed by our clinical,investigators who view ...
...Predictable, Extended Exposure with Sustained- ...O, April 17 Data from the first pivotal study of,...ional compound to treat,Restless Legs Syndrome (RL...toms of moderate-to-severe primary RLS compared to...ministered once-daily for 12 weeks., Data from th...
Other Medicine Technology:BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6
ABX Micros IM Hematology Analyzers
Sequitor™ Steerable Guidewire
Rio™ Aspiration Catheter
Reference Lab Interface (RLI)©
Medicine Products: